Protara Therapeutics, Inc. TARA
clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases.
order to create new development opportunities. We prioritize creativity, integrity and tenacity to expedite our goal of bringing life-changing
therapies to people with limited treatment options.
development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally
Last close
2.33
2026-10-23
Market cap
$137.7M
2026-06-30 share count
52-week range
2.28 - 7.82
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.34
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M | $12.0M | $3.9M | $11.8M | $21.7M | $18.9M |
| SG&A | $21.9M | $17.4M | $18.6M | $20.7M | $26.4M | $22.5M | $4.0M | $9.5M | $8.7M | $9.8M |
| Total operating expenses | $64.5M | $49.2M | $43.6M | $67.1M | $47.5M | $34.4M | $7.8M | $21.4M | $30.4M | $28.7M |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M | -$34.4M | -$7.8M | -$21.4M | -$30.4M | -$28.7M |
| Interest expense | — | — | — | — | $0 | $34.0K | — | — | — | — |
| Pre-tax income | $57.4M | $44.6M | — | — | — | — | -$15.0M | -$20.7M | -$30.0M | -$28.5M |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | -$47.3M | -$34.0M | -$7.8M | -$20.7M | -$30.0M | -$28.5M |
| EPS, basic | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | — | — | — | — | — |
| EPS, diluted | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | -4.70 | -3.04 | -45.80 | -2.13 | -1.72 |
| Shares, diluted (wtd. avg.) | 42.8M | 20.6M | 11.3M | 11.3M | 11.2M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $49.7M | $162.8M | $39.6M | $24.9M | $36.5M | $169.4M | $564.0K | $5.5M | $21.2M | $36.4M |
| Short-term investments | $105.9M | $7.5M | $26.0M | $60.2M | $55.5M | — | — | — | — | — |
| Total current assets | $159.5M | $172.2M | $68.7M | $86.1M | $93.1M | $169.4M | $764.0K | $23.2M | $43.5M | $42.8M |
| Property, plant and equipment | $759.0K | $1.0M | $1.3M | $1.6M | $1.7M | $1.2M | $459.0K | $263.0K | $259.0K | $372.0K |
| Goodwill | — | — | — | — | $29.5M | $29.5M | $29.5M | — | — | — |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M | $203.2M | $1.2M | $23.5M | $44.0M | $43.5M |
| Accounts payable | $3.5M | $4.4M | $2.4M | $1.6M | $954.0K | $914.0K | $716.0K | $441.0K | $291.0K | $556.0K |
| Short-term debt | — | — | — | — | $0 | $0 | — | — | — | — |
| Total current liabilities | $10.9M | $11.0M | $6.1M | $5.7M | $4.3M | $2.9M | $3.4M | $3.1M | $9.2M | $5.1M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M | $3.9M | $3.4M | $3.1M | $9.2M | $5.1M |
| Retained earnings | -$302.4M | -$245.0M | -$200.4M | -$160.0M | -$94.0M | -$46.8M | -$12.8M | -$210.5M | -$189.7M | -$159.8M |
| Total equity | $196.4M | $167.1M | $68.3M | $102.1M | $161.9M | $199.2M | -$2.1M | $4.8M | $34.7M | $38.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M | -$23.4M | -$5.0M | -$23.2M | -$22.4M | -$23.7M |
| Depreciation and amortisation | $362.0K | $332.0K | $341.0K | $248.0K | $117.0K | $103.0K | $16.0K | $115.0K | $148.0K | $123.0K |
| Stock-based compensation | $3.8M | $4.1M | $6.1M | $6.7M | $10.4M | $9.7M | $424.0K | $3.4M | $3.2M | $3.3M |
| Capital expenditure | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K |
| Investing cash flow | -$139.5M | $19.2M | $53.1M | $14.9M | -$98.2M | $2.8M | -$475.0K | $18.4M | -$16.1M | $19.9M |
| Financing cash flow | $82.7M | $139.9M | -$91.0K | -$90.0K | -$228.0K | $189.4M | $500.0K | $3.0M | $23.0M | $208.0K |
| Buybacks | — | — | $91.0K | $90.0K | $228.0K | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-048536.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$28.5M | -$30.0M | -$20.7M | -$7.8M | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |